Union Minister of Health and Family Welfare Jagat Prakash Nadda on Fridayy reviewed the progress and key initiatives of the Indian Pharmacopoeia Commission (IPC), underscoring its vital role in strengthening drug quality standards and pharmacovigilance in the country.
During the review meeting, the Health Minister commended IPC’s sustained efforts in reinforcing pharmacopoeial standards and monitoring drug safety, stating that these initiatives align with the government’s vision of Atmanirbhar Bharat and Viksit Bharat through self-reliance, scientific excellence and robust healthcare systems.
Shri Nadda highlighted the growing international recognition of the Indian Pharmacopoeia, which is now accepted in 19 countries. He said this reflects rising global confidence in India’s regulatory and scientific capabilities and strengthens the country’s position as the “Pharmacy of the World.”
The Minister emphasised that the Indian Pharmacopoeia continues to serve as a critical scientific and regulatory reference, ensuring uniform standards for the quality, safety and efficacy of medicines across the country, thereby safeguarding public health.
Shri Nadda also noted the crucial role played by IPC in implementing the Pharmacovigilance Programme of India (PvPI), which monitors adverse drug reactions and enhances patient safety. He appreciated IPC’s efforts to strengthen reporting mechanisms and build capacity among healthcare professionals.
The Health Minister encouraged the Commission to continue focusing on innovation, digitalisation and global harmonisation of standards in line with India’s long-term development goals, ensuring universal access to safe and quality medicines.
It was informed during the meeting that the 10th edition of the Indian Pharmacopoeia 2026 is scheduled to be launched by the Union Health Minister in the first week of January 2026.
The meeting was attended by senior officials from the Ministry of Health and Family Welfare, including Secretary-level officers. IPC Secretary-cum-Scientific Director Dr V. Kalaiselvan presented details of ongoing activities and reaffirmed the Commission’s commitment to strengthening pharmacopoeial and pharmacovigilance standards while expanding international collaboration.
